Navigation Links
Industry And FDA Leaders To Discuss The Evolving Science Of Cardiovascular Safety (CV) And Diabetic Drug Development
Date:7/29/2009

The Drug Information Association (DIA) will host a two-day workshop on Cardiovascular Safety and Development of Type 2 Diabetes Mellitus Medications from September 23-24, 2009 in Washington, DC.

Horsham, PA, (PRWEB) July 29, 2009 -- The Drug Information Association (DIA) will host a two-day workshop on Cardiovascular Safety and Development of Type 2 Diabetes Mellitus Medications from September 23-24, 2009 in Washington, DC.

The workshop will examine evolving scientific data surrounding CV safety and diabetic drug development, future methods to make development of these drugs more streamlined while ensuring safety. Session topics will include:

 
  • Type 2 Diabetes: Clinical implications, CV manifestations, and epidemiology
  • Therapies and targets for treatment of Diabetes Mellitus - potential implications on CV safety
  • Glycemic control - evidence for positive and negative impacts on CV and renal outcomes in Type 2 DM
  • New trial design approaches to assessing CV safety
  • Clinical evidence that T2DM diabetic drugs can increase CV risk
  • Diabetic drug development and CV safety
  • Approaches to clinical analysis of CV risk
  • Novel clinical trial approaches
  • Future approaches to assessing T2DM drug development and CV safety
  • QT experience as a model for furthering collaborative approaches/research in CV

"Recent data published in major medical journals suggests possible increase in cardiovascular (CV) risk associated with the use of certain drugs for the treatment of type 2 diabetes (T2DM)," explains Program Chair Philip T. Sager, MD, FACC, Vice President, Clinical Research, Cardiopulmonary and Metabolic Clinical Development, Gilead Sciences, Inc. "As a result, the Division of Metabolism and Endocrinology Products of the US Food and Drug Administration (FDA) issued a new guidance in December 2008 recommending that all new T2DM drugs demonstrate CV safety in appropriately designed and powered outcome studies."

About the Drug Information Association (DIA):

DIA serves more than 30,000 professionals involved in the biopharmaceutical industry and regulatory affairs worldwide. Through its domestic and international meetings, training courses, workshops and webinars, DIA provides a neutral global forum for the exchange of information critical to the advancement of the drug discovery and lifecycle management processes. Headquartered in Horsham, PA, USA, and with offices in Basel, Switzerland, Tokyo, Japan, Mumbai, India, and Beijing, China, the Association is led by its volunteer-based Board of Directors and executive management team. For more information, visit www.diahome.org or call 215-442-6100.

Contact:

Joe Krasowski
Drug Information Association
215-293-5812
www.diahome.org

###

Read the full story at http://www.prweb.com/releases/dia/cv_diabetes_workshop/prweb2687594.htm.


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved  

Related medicine news :

1. EDI Health Group Continues to Drive Growth of EDI Processing Services in the Dental Healthcare Industry Through Addition of 25 New Connections in the First Half of 2009
2. Globaltel Media Appoints Leading Healthcare Industry Veterans to Advisory Board
3. Career Step Launches New Exam Prep Course for Medical Transcription Industry Credential
4. Nexicon Technology to Protect Healthcare Industry
5. Kirby Lesters New KL60: The Pharmacy Industrys First and Only Compact, Fully-Automated Dispensing System
6. Giant Bud Banner Half the Size of Football Field Flies Sunday Protesting Hydroponics Industry Cartel Monopoly that's Harming California's Medical Marijuana Patients
7. The Ensign Group Announces Appointment of Healthcare Industry Leader to Board of Directors
8. THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT Highlights the Burgeoning Demographics of Orthopaedics and the Continuing Health of the Industry
9. Claricode Launches Medical Software Scholarship Program with a Notable Judging Panel of Industry Experts
10. Career Step Partners with Computer Learning Center to Help Students Gain Careers in Growing Healthcare Industry
11. Michael J. Fox Foundation Awards $3.8 Million To Drive Nine Industry Partnerships For Pre-Clinical Parkinsons Drug Development
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Industry And FDA Leaders To Discuss The Evolving Science Of Cardiovascular Safety (CV) And Diabetic Drug Development 
(Date:5/26/2016)... ... May 26, 2016 , ... Metcalf & Associates’ ... years of experience in leading technology and human resources operations for health care, ... Morrow-Fox will be featured on Metcalf’s VoiceAmerica radio show , Innovative Leaders ...
(Date:5/26/2016)... ... May 26, 2016 , ... Dr. LeRoy Perry’s recently authored whitepaper, ... mobile devices on the billions of users, hundreds of millions of whom are coming ... life threatening, the frequent and common action of looking down at hand-held technology devices ...
(Date:5/26/2016)... ... May 26, 2016 , ... Development Team of Pixel Film Studios ... , "This new layered style transition tool will keep a consistent flow to your ... Pixel Film Studios. , TranSweep is an all new layered style transition tool ...
(Date:5/26/2016)... ON (PRWEB) , ... May 26, 2016 , ... ... Organization, is proud to announce that it has successfully completed another Health Canada ... Branch Inspectorate of Health Canada. The rating resulted from a Good Manufacturing Practices ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... weekend to host their second pop-up shop for three consecutive weekends. The pop-up ... to the Santa Barbara community, a community full of women who appreciate the ...
Breaking Medicine News(10 mins):
(Date:5/24/2016)... Zealand , May 24, 2016 ... informatics solutions for the healthcare sector, has been named the ... Zealand Hi-Tech Awards 2016. Dr Bruce Davey ... acknowledgement for our team.  It,s really good to be recognised ... healthcare internationally. Our products are used in 35 countries around ...
(Date:5/24/2016)... , May 24, 2016 Celsion ... drug development company, today provided an update on ... escalating clinical trial combining GEN-1, the Company,s DNA-based ... treatment of newly-diagnosed patients with advanced ovarian cancer ... debulking surgery.  GEN-1 is an IL-12 DNA plasmid ...
(Date:5/24/2016)... 2016 The innovator of ... , s first dual therapy stent, introduces catheters ... OrbusNeich, a global company specializing in the provision ... include products to treat peripheral artery disease. The JADE™ ... devices for lower limb and arteriovenous (AV) fistula intervention. ...
Breaking Medicine Technology: